Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.65 |
| ▸ | HTR2A | P28223 | 15/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944807 | 0.87 | SLC6A4 (0.48) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL2881204 | 0.87 | SLC6A4 (0.55) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL3946409 | 0.86 | HTR2A (0.56) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL4019396 | 0.86 | HTR2A (0.56) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL8169606 | 0.86 | SLC6A4 (0.42) | SLC6A4HTR2AKCNH2HRH3 | |
| SCHEMBL7461612 | 0.85 | HTR2A (0.73) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL7107218 | 0.83 | HTR2A (0.46) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL7106388 | 0.80 | SLC6A4 (0.41) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL7246130 | 0.80 | MEN1 (0.42) | SLC6A4 | |
| SCHEMBL5837285 | 0.80 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596741-B2 | Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders. | PFIZER INC | 2003-07-22 | — | — | US | disclosed |
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055038-A1 | Novel biaryl ether derivatives useful as monoamine reuptake inhibitors | SLC6A2, SLC6A3, SLC18A2 | SLC6A4 6/4885HTR2A 24/4885KCNH2 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.